Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.5M
4M shares
52-week range
$1.33 – $11.73
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
67.59%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $3.5M | $2.2M | $2.0M | $4.8M | $6.0M | $5.4M | $1.83B |
| Operating income | −$5.9M | −$4.6M | −$12.8M | −$12.1M | −$14.6M | −$14.1M | −$8.1M |
| EBITDA | $0 | $0 | −$12.7M | −$12.1M | −$14.6M | $0 | −$8.0M |
| Net income | −$5.9M | −$4.6M | −$12.7M | −$12.1M | −$14.6M | −$14.1M | −$8.0M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -12.00 | -9.28 | -24.96 | -22.36 | -23.01 | -17.59 | -5.32 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $276000 | $-1.65 | $-1.65–$-1.65 | 1 |
| 2027 | $4M | $-1.77 | $-1.77–$-1.77 | 1 |
| 2028 | $25M | $-2.02 | $-2.02–$-2.02 | 1 |
| 2029 | $47M | $-1.76 | $-1.76–$-1.76 | 1 |
Forward consensus · source: Financial Modeling Prep
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
www.acurxpharma.comNo one on the platform currently holds ACXP.
No tracked institution reports a position in ACXP as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-08-05 | 1-for-20reverse |
No one on the platform has traded ACXP yet.
| $7M |
| — |
| BCLIBrainstorm Cell Therapeutics Inc. | $0.93 | -1.06% | $10M | — |
| CELZCreative Medical Technology Holdings, Inc. | $1.20 | -40.00% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ACXP all time low tomorrow? No matter, Luci and friends still getting paid.
View on StockTwits ↗$ACXP I think its the bottom here. Sorry for the fuzzy pic.
View on StockTwits ↗$ACXP explains FDA's new CDI guidance that could speed approval for its ibezapolstat antibiotic.
View on StockTwits ↗$ACXP should see under a dollar in a month at current rate of decline. Luci you suck.
View on StockTwits ↗$ACXP bill now up to 20 co-sponsors. https://www.congress.gov/bill/119th-congress/house-bill/7352/cosponsors?pageSort=lastToFirst&loclr=cga-bill
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-5-12-acurx-pharmaceuticals-inc-stock/ $ACXP Acurx Pharmaceuticals Earnings Transcript
View on StockTwits ↗$ACXP Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.62 up 71.16% YoY • On March 9, 2026, Acurx Pharmaceuticals announced a new clinical development initiative to expand the ibezapolstat program into recurrent C. difficile infection, with enrollment expected in the fourth quarter of this year.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.